To advance this field, future research should consist of large, phenotype-stratified randomized controlled trials (RCTs) and biomarker-driven RCTs designed around prominent T2DM phenotypes, such as insulin-resistant versus insulin-deficient profiles, or the presence of other significant comorbidities. The gene discussed is INS; the disease is type 2 diabetes mellitus.